32 results about "Vaccine Stability" patented technology

The invention relates to the preparative way of a kind of freeze-drying varicella vaccine, which has something to do with the biotechnology. The main making procedures include the following steps: the amplification and passage of Varicellavirus strain Oka to the MRC-5 strain in human's diploid cells; the harvest of the vaccine liquids; freeze-drying. The main property of the vaccine is that it adopts 0.5-1.2%(g/ml) gelatine, 0.6-1.2%(g/ml) glutamic sodium, 0.3-0.9%(g/ml) carbamide and 0.05-0.2%(g/ml) arginine as the freeze-drying protective agents, the previous concentrations stand for the final concentration of the protective agents. The good quality of the vaccine lies in that: the freeze-drying protective agents are developed by the producers themselves to make sure the stability of the vaccine. The result of storage stability test at 2-8DEG C shows that: there's no evident difference between the samples that stored for 18 months and the new-produced samples.

The present invention relates to the field of biological products, and in particular relates to a vaccine freeze-drying protective agent containing no gelatin and human albumin. The vaccine freeze-drying protective agent comprises 1.5%-10% of sucrose, 1.5%-3.5% of dextran, 1%-2% of sorbitol, 0.8%-1.2% of sodium glutamate and 0.2% to 1% of L-arginine in a vaccine semi-finished product, a matrix liquid for preparation of the vaccine freeze-drying protective agent is 199 culture medium or PBS buffer solution or water for injection, the vaccine freeze-drying protective agent contains no gelatin and human albumin, and the vaccine semi-finished product is a liquid vaccine before freeze-drying. The present invention also provides the use of the vaccine freeze-drying protective agent. When the vaccine freeze-drying protective agent is used for the preparation of a freeze-dried vaccine, the vaccine freeze-drying protective agent can improve the vaccine stability during freeze-drying and storage processes, greatly improves the freeze-dried vaccine safety for human, and reduces adverse effects of the vaccine.

Disclosed is a recombined chicken pox virus vaccine rFPV-12LSH5H9, its construction method and use, wherein the construction process consists of placing AIV HA gene fragment containing H5 hypotype and H9 hypotype onto the downstream of right promotors, inserting into chicken poxviridae expression vector p12-18 containing FPV duplicated non-indispensable fragment FPV1-2 and reported genes through backside cascade connection to construct transition vector p12LSH5H9, then transforming chick embryo desmocyte infected with wt-FPV with the transition vector p12LSH5H9, and obtaining co-expression H5 and H9 hypotype AIV HA gene rFPV-12LSH5H9 through consanguinity recombination.

Disclosed is a recombined chicken pox virus vaccine rPFV-12LSH9A, preparation process and use, wherein the construction process consists of placing AIV HA gene fragment containing H9 hypotype onto the downstream of right promotors, inserting into chicken poxviridae expression vector p12-18 containing FPV duplicated non-indispensable fragment FPV1-2 and reported genes to construct transition vector, then transforming chick embryo desmocyte infected with wt-FPV with the transition vector, and obtaining rFPV expressing H9 hypotype AIV HA gene through consanguinity recombination, i.e. recombinant chicken poxviridae vaccine rFPV-12LSH9A.

A freeze-dried carrier vaccine of HIV recombinant MVA virus features high stability. It is prepared from the liquid-type carrier vaccine of HIV recombinant MVA virus through adding the protecting agent prepared from mycose, mannitol, dextran and inositol, stirring and vacuum freeze drying.

The invention provides a fusion protein and a nucleotide sequence thereof. The fusion protein comprises a toxoplasma cyclophilin protein subunit and a T cell epitope. The invention also provides a vaccine for preventing toxoplasmosis of dogs by using the fusion protein and a vaccine composition of the vaccine. The invention has the beneficial effects that the fusion protein has the characteristicsof high expression quantity and high immunogenicity; and the vaccine and the vaccine composition can effectively prevent canine toxoplasmosis and have high vaccine stability.

The invention provides fusion protein and a nucleotide sequence thereof. The fusion protein comprises a toxoplasma P30 protein subunit and a T cell antigenic epitope. The invention further provides avaccine using the fusion protein to prevent abortion of pregnant sows due to toxoplasmosis and a vaccine composition thereof. The fusion protein has the beneficial effects of the characteristics of high expression quantity and high immunogenicity. The vaccine and the vaccine composition can effectively prevent abortion of the pregnant sows due to the toxoplasmosis and are high in vaccine stability.

The invention discloses a preparation method for freeze-dried b-type haemophilus influenza conjugate vaccines, which comprises the following steps of: preparing and separately packaging semi-finished product solution of the conjugate vaccine; putting the semi-finished product solution of the conjugate vaccine into a freeze-drying machine to be freeze-dried: firstly prefreezing for 2-4 hours, vacuumizing after prefreezing, regulating the temperature of the vacuum freeze-drying machine to be 30-35 DEG C below zero after vacuumizing, keeping the temperature for 10 hours, raising the temperature of a shelf to 30 DEG C at the speed of 5 DEG C/hour, and keeping the temperature of 30 DEG C for 3.8-4.2 hours; and taking out the freeze-dried conjugate vaccine to obtain a finished product. The vaccine prepared in the method disclosed by the invention meets the requirement, and conventional liquid dosage form is replaced by the freeze-dried Hib conjugate vaccine which has the characteristics of convenience in storage, transportation and use, good stability, long period of validity and the like.

The invention provides a method for predicting stability of a new crown vaccine based on a quantum gating recurrent neural network, and belongs to the technical field of quantum computing. According to the method, a quantum gating circulating unit is used for resetting and updating a basic group in an RNA sequence and a corresponding hidden state, a new hidden state is generated, and the reaction rate and degradation rate of the RNA sequence at different positions are output, so that the stability of the new crown vaccine is predicted, and therefore, the stability of the new crown vaccine is predicted. The method meets the requirement for establishing the long-term and short-term dependency relationship of the sequence by a gated recurrent neural network algorithm, and is low in computing resource consumption, so that the method is widely applied to cooperative work of a quantum chip and an electronic chip.

The present invention discloses an immunogenic composition containing a rabbit staphylococcal antigen, and a preparation method and an application thereof. The immunogenic composition uses a mixture of a rabbit staphylococcal antigen, a dispersion carrier and an aqueous printing adjuvant as printing spray liquid and freeze-dried protective powder as accessory powder, and the printing spray liquidis repeatedly sprayed on each layer of the accessory powder by a 3D printing technique to obtain the immunogenic composition containing the rabbit staphylococcal antigen with a three-dimensional structure. The immunogenic composition prepared by the method has good immunogenic activity and immunoprotection, can be effectively used for prevention and treatment of rabbit staphylococcus aureus, and has an immune protection rate up to 100%, and the vaccine is good in stability and not liable to be inactivated.

The invention belongs to the field of biomedicine, and particularly relates to an application of MG132 as a vaccine production synergist and a stabilizing agent. The MG132 can increase the expressionlevel of ribonucleic acid virus structural protein VP3, further promotes the assembly of virus-like particles, and can be applied to virus-like particle expression synergists, virus-like particle production synergists and the stabilizing agents of related vaccines to promote vaccine production and improve vaccine stability.

Disclosed is a method for protecting viral vaccine and improving thermal stability utilizing heavy water, which consists of choosing the concentration of heavy water (D2O) by a predetermined proportion, processing vaccines at different stages during vaccine production, deuterating the cells with heavy water, thus obtaining deuterated virus vaccine, or suspending the virus vaccine directly with high concentration heavy water (D2O).

The invention provides a new antigen RNA and immunologic adjuvant poly (I: C) composite vaccine. The composite vaccine comprises PEG-PLL-PLLeu self-assembled nano-micelle, a new antigen RNA vaccine and an immunologic adjuvant poly (I: C), wherein the new antigen RNA vaccine and the immunologic adjuvant poly (I: C) are loaded on the PEG-PLL-PLLeu self-assembled nano-micelle; and the nucleotide sequence of the new antigen RNA is shown as SEQ ID NO. 1. The new antigen RNA and immunologic adjuvant poly (I: C) composite vaccine provided by the invention is good in stability, high in translation efficiency, easy in expression product transfer and good in treatment effect.

The invention especially relates to a method for producing a live vaccine against pseudorabies in swine from a continuous cell line, belonging to the technical field of biological products for livestock. The continuous cell line used in the invention is Vero cells. The method comprises the following steps: passage and culture of cells for vaccine preparation; propagation of virus seeds of the cells; propagation of virus liquid used for vaccine preparation; and vaccine preparation, split charging and freeze-drying. Porcine pseudorabies viruses obtained by using the method re high in content and titer; and the eventually prepared vaccine has high stability and long shelf life.